Trials / Completed
CompletedNCT00216255
EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study
An 8-week, Double-blind, Randomized, Multicenter, Flexible-dose, Placebo Controlled Pilot Study of Pagoclone in Patients With PDS Followed by a 52-week Open-label Extension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Endo Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to determine the effects of pagoclone on the symptoms of Persistent Developmental Stuttering, using a flexible dosing titration regimen on persistent developmental stuttering in patients 18 to 65 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pagoclone | |
| DRUG | Placebo |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2005-09-22
- Last updated
- 2012-09-03
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00216255. Inclusion in this directory is not an endorsement.